{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=inactivated+influenza+vaccine",
    "query": {
      "intervention": "inactivated influenza vaccine"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 308,
    "total_pages": 31,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=inactivated+influenza+vaccine&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T06:32:57.025Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02124161",
      "title": "Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE"
      ],
      "interventions": [
        {
          "name": "13-valent pneumococcal conjugate vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Seasonal Inactivated Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 882,
      "start_date": "2014-09",
      "completion_date": "2015-05",
      "has_results": true,
      "last_update_posted_date": "2016-07-01",
      "last_synced_at": "2026-10-08T06:32:57.025Z",
      "location_count": 44,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 37 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02124161"
    },
    {
      "nct_id": "NCT06695130",
      "title": "Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "COVID-19 Immunization",
        "Influenza Immunization"
      ],
      "interventions": [
        {
          "name": "RIV (recombinant influenza vaccine)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rC19 (dose 1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RIV + rC19 (dose 1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RIV + rC19 (dose 2)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RIV + rC19 (dose 3)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RIV + rC19 (dose 4)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (0.9% NaCl)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 980,
      "start_date": "2024-11-18",
      "completion_date": "2026-04-03",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-10-08T06:32:57.025Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Cerritos, California • Vista, California + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Vista",
          "state": "California"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06695130"
    },
    {
      "nct_id": "NCT00133536",
      "title": "A/H5N1 Vaccine in Healthy Children Aged 2-9 Years",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Influenza A/H5N1 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "9 Years",
        "sex": "ALL",
        "summary": "2 Years to 9 Years"
      },
      "enrollment_count": 157,
      "start_date": "2006-01",
      "completion_date": "2007-04",
      "has_results": false,
      "last_update_posted_date": "2010-08-27",
      "last_synced_at": "2026-10-08T06:32:57.025Z",
      "location_count": 4,
      "location_summary": "Torrance, California • Baltimore, Maryland • St Louis, Missouri + 1 more",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00133536"
    },
    {
      "nct_id": "NCT03756246",
      "title": "Influenza Vaccine as a Novel Experimental Model of the Behavioral Immune Response in Depression",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Depression",
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Texas at Austin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 75,
      "start_date": "2019-06-10",
      "completion_date": "2021-05",
      "has_results": false,
      "last_update_posted_date": "2019-06-27",
      "last_synced_at": "2026-10-08T06:32:57.025Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03756246"
    },
    {
      "nct_id": "NCT05755620",
      "title": "A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Influenza Virus Quadrivalent Inactivated Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sodium Chloride, 0.9%",
          "type": "OTHER"
        },
        {
          "name": "VRC-FLUNPF099-00-VP (H1ssF_3928)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 50,
      "start_date": "2023-04-05",
      "completion_date": "2025-10-03",
      "has_results": false,
      "last_update_posted_date": "2026-06-18",
      "last_synced_at": "2026-10-08T06:32:57.025Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05755620"
    },
    {
      "nct_id": "NCT02783170",
      "title": "Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pregnancy"
      ],
      "interventions": [
        {
          "name": "Tetanus, Diphtheria, and Pertussis Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "2016-2017 Quadrivalent Inactivated Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "2017-2018 Quadrivalent Inactivated Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 81,
      "start_date": "2016-09",
      "completion_date": "2018-05-10",
      "has_results": true,
      "last_update_posted_date": "2025-07-28",
      "last_synced_at": "2026-10-08T06:32:57.025Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia • Durham, North Carolina • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02783170"
    },
    {
      "nct_id": "NCT00959049",
      "title": "A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "CSL's Influenza Virus Vaccine (Afluria)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Influenza Virus Vaccine (Fluzone)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Months to 17 Years"
      },
      "enrollment_count": 1474,
      "start_date": "2009-09",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2017-05-16",
      "last_synced_at": "2026-10-08T06:32:57.025Z",
      "location_count": 23,
      "location_summary": "Chandler, Arizona • Harrisburg, Arkansas • Jonesboro, Arkansas + 16 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Harrisburg",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Mountain Home",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00959049"
    },
    {
      "nct_id": "NCT02967393",
      "title": "Influenza Vaccine Feasibility Study in Children With Persistent Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthmatic"
      ],
      "interventions": [
        {
          "name": "ccIIV4",
          "type": "DRUG"
        },
        {
          "name": "IIV4",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "5 Years to 11 Years"
      },
      "enrollment_count": 40,
      "start_date": "2016-10-10",
      "completion_date": "2017-02-01",
      "has_results": true,
      "last_update_posted_date": "2018-04-23",
      "last_synced_at": "2026-10-08T06:32:57.025Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia • Durham, North Carolina • Cincinnati, Ohio + 1 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02967393"
    },
    {
      "nct_id": "NCT03816878",
      "title": "Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "H5N1 pISV",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 32,
      "start_date": "2019-01-08",
      "completion_date": "2020-03-17",
      "has_results": true,
      "last_update_posted_date": "2025-09-22",
      "last_synced_at": "2026-10-08T06:32:57.025Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03816878"
    },
    {
      "nct_id": "NCT05007041",
      "title": "Simultaneous RZV and aIIV4 Vaccination",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pain",
        "Quality of Life",
        "Injection Site Reaction",
        "Adverse Drug Event"
      ],
      "interventions": [
        {
          "name": "FLUAD® Quadrivalent",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone® High-Dose Quadrivalent",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SHINGRIX®",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 267,
      "start_date": "2021-09-21",
      "completion_date": "2023-06-08",
      "has_results": true,
      "last_update_posted_date": "2024-07-11",
      "last_synced_at": "2026-10-08T06:32:57.025Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Durham, North Carolina",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05007041"
    }
  ]
}